Welcome to IPE. This site uses cookies. Read our policy.

  • Skip to main content
  • Skip to navigation
IPE
IPE Jan 2021 masthead Current edition

IPE magazine January 2021

SEARCH SPONSOR
Baillie Gifford
IPE
Mast navigation
  • Register
  • Sign In
Search our site
Menu
Close menu
  • Home
  • News
  • Countries
  • Reports
  • Strategies
  • ESG
  • Interviews
  • Comment
  • Quest
  • Events
    • Back to parent navigation item
    • Events
    • IPE Awards
    • IPE Awards Winners
    • IPE Events
    • IPE Hall of Fame
    • Industry Events
    • Webcasts
  • Hub
  • IPE Real Assets
  • Home
  • News
    • Top 500 cover index
      Global managers register largest yearly AUM increase in 2019
  • Countries
  • Reports
  • Strategies
  • ESG
  • Interviews
  • Comment
  • Quest
  • Events
      • IPE Awards
      • IPE Awards Winners
      • IPE Events
      • IPE Hall of Fame
      • Industry Events
      • Webcasts
  • Hub
  • IPE Real Assets
  • More navigation items

Search results

Your search for Novartis found 120 results. Displaying results 1 to 10 | Search Help

Use the filters to refine the results. Or use quotation marks to search for an exact phrase - e.g. "pocket money". Or use NOT to reduce unwanted matches, e.g. Paris NOT Texas, will find matches for Paris, but exclude stories which also have the word Texas.
Filter search

Filters

Keyword

Filter your search

By Type

No selections available

By date

No selections available
  • Date range
  • BNP Paribas Real Estate Property Development sells the new NOVARTIS headquarters of 42 200 sqm to Korea Investment & Securities

    BNP Paribas Real Estate Property Development sells the new NOVARTIS headquarters of 42 200 sqm to Korea Investment & Securities

    Reference Hub2017-01-02T11:57:00ZBy BNP Paribas Real Estate Investment Management [Europe]

    On December 23th 2016, BNP Paribas Real Estate Property Development signed a sale for the new NOVARTIS headquarters located in the Rueil-sur-Seine business district, in Rueil-Malmaison.

  • Save articleSwitzerland's Ethos presses for review of Novartis' remuneration policy
    News

    Switzerland's Ethos presses for review of Novartis' remuneration policy

    2011-02-22T15:15:00Z

    Foundation argued that remuneration should not reward risk-taking.

  • Save article
    News

    Novartis misses benchmark

    2007-05-30T16:02:55Z

    SWITZERLAND – Novartis’ CHF14.3bn (€8.7bn) pension fund has reported a return of just 2% for 2006 – below both the 6.6% average for other Swiss schemes and its own 3% benchmark.

  • Save article
    News

    Ethos plans Novartis revolt

    2007-02-21T16:36:57Z

    SWITZERLAND – Socially-responsible manager Ethos says it will oppose the re-election of a senior official at the Swiss pharmaceuticals giant Novartis during the firm’s annual shareholder meeting on March 6.

  • Save article
    News

    Oxfam starts Novartis campaign

    2007-01-23T16:53:29Z

    UK – Responsible investment campaigners FairPensions and international development agency Oxfam, have asked institutional investors to use their shareholder rights to put pressure on pharmaceutical firms.

  • Save article
    News

    New head at €8bn Novartis scheme

    2006-10-10T16:11:56Z

    SWITZERLAND – Gino Pfister has stepped down as director of the Novartis pension fund, one of Switzerland’s biggest with CHF14.6bn (€8.6bn) in assets.

  • Save article
    News

    Novartis pension fund returns 6.2%

    2006-06-02T03:39:00Z

    SWITZERLAND – Novartis’ pension fund, one of Switzerland’s biggest with CHF14.6bn (€9.3bn) in assets, has reported a return of 6.2% for 2005 - well below the 11% average for other Swiss schemes.

  • Save articleSwiss 1e pension plans spark appetite for younger generations
    News

    Swiss 1e pension plans spark appetite for younger generations

    2020-08-21T14:43:00Z

    Large companies with 1e solutions include CS and Novartis

  • Save article
    Features

    Novartis shifts from 'bricks and mortar'

    December 2002 (Magazine)

    The SFr16.8bn (e11.4bn) pension scheme of Swiss pharmaceutical giant, Novartis, holds real estate assets that comprise 12% of the fund’s assets. Earlier this year, it completed a major transition in the approach to its property portfolio, which allowed the fund to maintain its exposure to this asset class, while enabling ...

  • Save article
    Features

    Novartis fund makes move from concrete to paper

    January 2002 (Magazine)

    Pension funds in Switzerland have a long tradition of investing in property, and the team responsible for the Sfr18bn(e12bn) Novartis pension fund is not exception. The Basle-based pension fund has for years had a significant exposure to real estate, around 12% of the total portfolio, through direct holdings in property, ...

  • Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page
  • Contact Us
  • Digital Editions and Subscriptions
  • IPE Editorial
  • Company Overview
  • Print advertising rates and specifications
  • Digital advertising technical specifications (pdf)
  • IPE Media Pack 2021
  • Print Copies during Coronavirus
  • Advertising terms and conditions
footer-logo

Copyright © 1997–2020 IPE International Publishers Limited, Registered in England, Reg No. 3233596, VAT No. 685 1784 92. Registered Office: 1 Kentish Buildings, 125 Borough High Street, London SE1 1NP

  • Previous issues
  • Contributors A-Z
  • Subjects A-Z
  • Privacy policy
  • Cookie policy
  • Acceptable use policy
  • Terms & conditions
  • Subscribe to IPE
  • Follow us on Twitter
  • Join us on LinkedIn
Tweets by IPEnews

Site powered by Webvision Cloud